NanoString Breast Cancer Intrinsic Subtyping Assay update

NanoString began a second validation study to evaluate its NanoString Breast Cancer Intrinsic Subtyping Assay on samples from more than 1,000 postmenopausal female patients with hormone receptor-posit...